- Q1 2024 SpringWorks Therapeutics Inc Earnings Call TranscriptMay 02, 2024$43.35 (-7.45%)Earnings
- SpringWorks Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- SpringWorks Therapeutics to Discuss The ReNeu Topline Data TranscriptNov 16, 2023
- SpringWorks Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- SpringWorks Therapeutics Inc at TD Cowen Oncology Innovation Summit (Virtual) TranscriptMay 31, 2023
- SpringWorks Therapeutics Inc at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- SpringWorks Therapeutics Inc at Cowen Health Care Conference TranscriptMar 07, 2023
- SpringWorks Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- SpringWorks Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 29, 2022
- SpringWorks Therapeutics Inc at H.C. Wainwright Precision Oncology Conference (Virtual) TranscriptNov 14, 2022
- SpringWorks Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- SpringWorks Therapeutics Inc R&D Day (Virtual) TranscriptJun 10, 2022
- SpringWorks Therapeutics Inc To Discuss The DeFi Trial Data Call TranscriptMay 24, 2022
- SpringWorks Therapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) TranscriptFeb 10, 2022
- SpringWorks Therapeutics Inc and the ReNeu Trial for NF1-Related Plexiform Neurofibromas TranscriptJul 15, 2021
- SpringWorks Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 08, 2021
- SpringWorks Therapeutics to Discuss the Reneu Trial Data and Program Update Call TranscriptFeb 25, 2021
- SpringWorks Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
- SpringWorks Therapeutics Inc Clinical Trials TranscriptOct 13, 2020
SpringWorks Therapeutics Inc To Discuss The DeFi Trial Data Call Transcript
Good morning and welcome to the SpringWorks Therapeutics conference call to discuss the Phase 3 DeFi topline -- sorry, Phase 3 DeFi trial topline results. At this time, I would like to turn the call over to Kim Diamond, Vice President of Communications and Investor Relations.
Thank you, Kevin, and welcome to the SpringWorks Therapeutics conference call to discuss the topline data from our Phase 3 DeFi trial evaluating nirogacestat in adult patients with progressing desmoid tumors. Leading the call today will be SpringWorks' CEO, Saqib Islam. Saqib is joined by our Chief Development Officer, Dr. Mary Smith; and our Chief Operating Officer, Dr. Badreddin Edris.
Following our prepared remarks, we will be taking questions. Slides to accompany this conference call are posted in the Investors and Media section of our website at www.springworkstx.com and an audio webcast with the corresponding slides is also available
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)